Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 44Recurrence 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Neoplasms, Plasma Cell 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma 3Lung Neoplasms 3Leukemia 3Immunoglobulin Light-chain Amyloidosis 3Amyloidosis 3Myelodysplastic Syndromes 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Proteostasis Deficiencies 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Oropharyngeal Neoplasms 1Neoplasms 1Melanoma 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphodepleting Chemotherapy 1

Interventions

ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1RG7388 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Chromosome 17 deletion × Calcium Dobesilate × Clear all
NCT02633059 2024-09-19

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
33 enrolled 26 charts
Plasma cell

Chromosome 17 deletion, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡